216 related articles for article (PubMed ID: 10523073)
21. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
[TBL] [Abstract][Full Text] [Related]
24. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
[TBL] [Abstract][Full Text] [Related]
25. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
[TBL] [Abstract][Full Text] [Related]
26. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
[TBL] [Abstract][Full Text] [Related]
27. Population analysis of pharmacogenetic polymorphisms related to acute lymphoblastic leukemia drug treatment.
Chiabai MA; Lins TC; Pogue R; Pereira RW
Dis Markers; 2012; 32(4):247-53. PubMed ID: 22430191
[TBL] [Abstract][Full Text] [Related]
28. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
29. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K
Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820
[TBL] [Abstract][Full Text] [Related]
30. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
[TBL] [Abstract][Full Text] [Related]
31. Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia.
Gervasini G; Mota-Zamorano S
Curr Drug Metab; 2019; 20(4):313-330. PubMed ID: 30706807
[TBL] [Abstract][Full Text] [Related]
32. Delayed elimination of methotrexate in a patient receiving ciprofloxacin.
Aouinti I; Gaïes E; Trabelsi S; Salouage I; Jebabli N; Charfi R; Lakhal M; Klouz A
Therapie; 2013; 68(3):175-7. PubMed ID: 23886465
[No Abstract] [Full Text] [Related]
33. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
34. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
35. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
[TBL] [Abstract][Full Text] [Related]
36. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
37. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
38. The role of 5'nucleotidase in therapy-resistance of childhood leukemia.
Pieters R; Veerman AJ
Med Hypotheses; 1988 Sep; 27(1):77-80. PubMed ID: 2849709
[TBL] [Abstract][Full Text] [Related]
39. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S; Marable M; Huang RS
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate plasma pharmacokinetics: importance of assay method.
Eksborg S; Albertioni F; Rask C; Beck O; Palm C; Schroeder H; Peterson C
Cancer Lett; 1996 Nov; 108(2):163-9. PubMed ID: 8973590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]